




RealRate

PHARMACEUTICAL 2023

ANI Pharmaceuticals INC
Rank 252 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of ANI Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANI Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 62% points. The greatest weakness of ANI Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is 244%, being 0.52% points below the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	344,261	Assets	760,087
Cost of Goods Sold	0	Liabilities	421,547
Intangible Assets	279,856	Expenses	336,899
Liabilities, Current	99,439	Revenues	316,385
Liabilities, Non-Current	287,050	Stockholders Equity	338,540
Other Assets	92,724	Net Income	-47,896
Other Compr. Net Income	15,223	Comprehensive Net Income	-40,284
Other Expenses	190,537	BaseVar	938,762
Other Liabilities	35,058	ECR before LimitedLiability	118%
Other Net Income	-27,382	Economic Capital Ratio	244%
Other Revenues	316,385		
Property and Equipment	43,246		
Research and Development	22,318		
Selling, General and Administrative Expense	124,044		